Background-Therapeutic angiogenesis is a promising approach for the treatment of cardiovascular diseases, including myocardial infarction and chronic heart failure. We aimed to improve proangiogenic therapies by identifying novel arteriogenic growth factor combinations, developing injectable delivery systems for spatiotemporally controlled growth factor release, and evaluating functional consequences of targeted intramyocardial growth factor delivery in chronic heart failure. Methods and Results-First, we observed that fibroblast growth factor and hepatocyte growth factor synergistically stimulate vascular cell migration and proliferation in vitro. Using 2 in vivo angiogenesis assays (nϭ5 mice per group), we found that the growth factor combination results in a more potent and durable angiogenic response than either growth factor used alone. Furthermore, we determined that the molecular mechanisms involve potentiation of Akt and mitogen-activated protein kinase signal transduction pathways, as well as upregulation of angiogenic growth factor receptors. Next, we developed crosslinked albumin-alginate microcapsules that sequentially release fibroblast growth factor-2 and hepatocyte growth factor. Finally, in a rat model of chronic heart failure induced by coronary ligation (nϭ14 to 15 rats per group), we found that intramyocardial slow release of fibroblast growth factor-2 with hepatocyte growth factor potently stimulates angiogenesis and arteriogenesis and prevents cardiac hypertrophy and fibrosis, as determined by immunohistochemistry, leading to improved cardiac perfusion after 3 months, as shown by magnetic resonance imaging. These multiple beneficial effects resulted in reduced adverse cardiac remodeling and improved left ventricular function, as revealed by echocardiography. Conclusion-Our data showing the selective advantage of using fibroblast growth factor-2 together with hepatocyte growth factor suggest that this growth factor combination may constitute an efficient novel treatment for chronic heart failure. (Circulation. 2011;124:1059-1069.)
T he presence of coronary collaterals is a favorable prognostic factor in coronary artery disease, associated with reduced myocardial infarct size and increased patient survival. 1 However, the fact that an estimated 66% to 75% of coronary artery disease patients have insufficient coronary collaterals presents an incentive for therapeutic stimulation of arterial blood vessel growth, ie, collaterogenesis or arteriogenesis. 2 In addition, Ϸ30% of myocardial infarction (MI) patients display inadequate myocardial perfusion (ie, the no-reflow phenomenon), 3 suggesting that therapeutic stimulation of smaller-caliber blood vessel growth, ie, angiogenesis, also is a valid treatment approach for coronary artery disease. 4 Chronic heart failure (CHF), an in-creasingly common consequence of MI and other cardiomyopathies, is characterized by extensive cardiac hypertrophy and fibrosis. It has been suggested that the switch between reversible physiological and irreversible pathological cardiac hypertrophy depends on angiogenesis. 5 Thus, therapeutic stimulation of arteriogenesis and/or angiogenesis is an attractive common target in cardiovascular diseases. disease were initiated. Today, 10 years later, there is still no approved treatment for patients who are poor candidates for surgical revascularization or have distal diffuse ischemic disease. Indeed, double-blind controlled clinical trials in coronary artery disease patients, based on administration of vascular endothelial growth factor or fibroblast growth factor-2 (FGF-2), have failed to demonstrate a durable effect. 6, 7 The main problems of current proangiogenic approaches include the limited duration of the therapy achieved with bolus delivery of naked proteins or gene delivery vectors, the high costs associated with protein therapy because of the general need for large doses, the transient effects of treatment likely due to the generation of unstable blood vessels that regress over time, and important safety issues related to the possibility of inadvertent stimulation of angiogenesis in distant, dormant micrometastases or in diabetic retinopathy. 8, 9 Responses to these challenges include the proposition that single growth factor therapy be replaced by growth factor combinations to stimulate the generation of mature and stable blood vessels, including large-caliber collateral arteries, 10 or gaining control over growth factor release rates using delivery vectors that allow prolonged angiogenic stimulation. [11] [12] [13] Of note, most experimental approaches have involved delivery of supraphysiological doses of angiogenic growth factors, often in the range of 10 to 100 g/kg. However, it seems that it is not the total growth factor dose that determines the outcome of angiogenic therapy; rather, local microenvironmental concentration gradients are important for achieving functional revascularization responses. 14 Here, we report a new therapeutic strategy specifically designed to stimulate angiogenesis and arteriogenesis in the failing heart based on targeted, intramyocardial, sequential slow release of a novel angiogenic growth factor combination, FGF-2 and hepatocyte growth factor (HGF), using albumin-alginate microcapsules.
Methods
A detailed description of all methods and reagents used for the experiments is provided in the online-only Data Supplement.
Cell Migration and Proliferation
Briefly, cells were pretreated with FGF-2 or HGF and then added to the upper wells of a modified Boyden 48-well chamber. The lower wells contained FGF-2 or HGF. Cells migrated across the membrane during 6 to 12 hours at 37°C. Results are reported as number of migrating cells per 1 mm 2 (nϭ6). For analyses of cell proliferation, heart microvascular endothelial cells (HMEs), human microvascular cardiac endothelial cells (HMEC-Cs), and rat aortic smooth muscle cells (SMCs) were pretreated with FGF-2 or HGF, added to 24-well plates, and stimulated with FGF-2 or HGF. Cell numbers were estimated with the WST-1 assay.
Corneal Angiogenesis Assay
The mouse corneal assay was performed as previously described in C57Bl/6 mice and as approved by the North Stockholm Animal Ethics Committee. 15 Briefly, sucrose aluminum sulfate micropellets containing recombinant human HGF and/or FGF-2 were implanted into mice corneas (nϭ5 per group). The eyes were examined on days 5, 25, and 40 and Ϸ1 year after pellet implantation.
Albumin-Alginate Microcapsules
Albumin-alginate microcapsules were prepared with a modified version of the previously described interfacial cross-linking method 16 and as outlined in the Methods section in the online-only Data Supplement.
In Vitro Growth Factor Release
Briefly, lyophilized microcapsules were loaded with growth factors by imbibition, 17 with 1 g growth factor per 1 mg microcapsules (Ϸ35Ј000 particles). Growth factor release after incubation in extracellular fluid mimetic release buffer was quantified by ELISA. Data are presented as mean amount (nanograms) of growth factor released per day per 1 mg microcapsules (nϭ3).
Matrigel Plug Model
Growth factor-reduced Matrigel was used to evaluate angiogenic responses as outlined in the Methods section in the online-only Data Supplement and in accordance with National Institutes of Health guidelines, European Communities Council directives (86/609/ EEC), and French National legislation (ethical approval No. 76-114). Briefly, 500 L Matrigel was mixed with microcapsules loaded with growth factors as above. Controls contained Matrigel mixed with buffer or microcapsules without growth factors. The Matrigel mixture was subcutaneously injected in male Balb/c mice (nϭ5 per group). After 3 weeks, Matrigel plugs were harvested and snap-frozen.
Chronic Heart Failure Model
We induced MI in anesthetized, mechanically ventilated male Wistar rats by ligation of the proximal left coronary artery after a left thoracotomy (nϭ22 rats per group) as previously described 18, 19 and in accordance with National Institutes of Health guidelines, European Communities Council directives (86/609/EEC), and French National legislation (ethical approval No. 76 -114). Immediately after ligation, microcapsules loaded with growth factors, as above, were injected in 3 spots (23 L per spot) along the infarct border zone on the right anterior side of the left ventricular (LV) free wall adjacent to the septum. The total amount of growth factor administered per heart was 125 ng HGF or 500 ng FGF-2 alone or in combination. Controls were injected with the same numbers of microcapsules without growth factor. At the time of death, hearts were arrested in diastole by immersion in ice-cold saturated potassium chloride buffer.
Histochemistry
Collagen density and MI size were determined in heart cryosections stained with Sirius Red as previously described 18 and as outlined in the Methods section in the online-only Data Supplement. Collagen content was calculated as percentage of collagen area to total area of the image (nϭ14 to 15 animals per group). Infarct size was calculated as follows: total infarction perimeter/(epicardial LV perimeterϩendocardial LV perimeter)ϫ100. For immunohistochemical analyses, cryosections were stained according to standard protocols as detailed in the Methods section in the online-only Data Supplement. Micrographs were processed by an operator blinded to the treatment groups with Image Pro-Plus, AxioVision, or Adobe Photoshop image analysis software. Vessel density and vessel maturity were quantified as the number of CD31 ϩ vessels and smooth muscle active-positive (SMA ϩ ) vessels per 1 mm 2 , respectively. Matrigel plug vessel content was calculated as percentage of vascularized area to total section area. Endothelial proliferation was analyzed by Ki67 and CD31 double labeling and presented as number of Ki67 ϩ endothelial cells (ECs) per 1 mm 2 . Cardiomyocyte sizes were measured in wheat germ agglutinin-stained sections. The ratio of vessel to cardiomyocyte was calculated as the number of vessels to the number of cardiomyocytes per 1 mm 2 .
Semiquantitative Fluorescence Microscopy
Angiogenic growth factor receptor protein expression levels were determined in Matrigel plugs implanted with microcapsules loaded with FGF-2 or HGF as above and detailed in the Methods section in the online-only Data Supplement. Briefly, sections were double labeled for either c-Met or FGF receptor-1 (FGFR-1) in conjunction with CD31. Micrographs obtained with a Leica SP5 TCS X inverted confocal microscope were analyzed with Bitplane Imaris software to determine maximal relative levels of signal intensity in regions of interest centered on individual blood vessels.
Confocal Imaging of Growth Factor Distribution
Recombinant human FGF-2 or recombinant mouse HGF (20 g) was fluorescently labeled with an Alexa-555. Lyophilized microcapsules were loaded with fluorescent growth factors as above. Microcapsules were either imaged directly by confocal microscopy or injected into the viable zone of the LV after coronary ligation in rats as above. Cardiac samples retrieved at 1 or 3 weeks after MI were imaged with a Leica SP5 TCS X inverted confocal microscope. Images were processed with Leica LAS AF software.
Magnetic Resonance Imaging
Cardiac perfusion was assessed by arterial spin-labeling magnetic resonance imaging with a 4.7-T small animal magnet (Biospec 47/40 advanced II, Brucker, Ettlingen, Germany). Briefly, the perfusion sequence was run in the short-axis plane, allowing determination of myocardial tissue perfusion. Global and slice-selective spin inversion recovery T1* (fitted time constant) maps were acquired. 20 Perfusion images were analyzed with ParaVision 5.0 software (Brucker) by 2 independent observers, and regional perfusion in the treated area of the LV was calculated as described. 21 
Echocardiography
Animals (nϭ14 to 15 rats per group and 8 age-matched shamoperated rats) were examined at 1 and 3 months after MI by transthoracic echocardiography as previously described. 18 Measurements performed by a single echocardiographer blinded to the treatment groups were made in accordance with the conventions of the American Society of Echocardiography and as detailed in the Methods section in the online-only Data Supplement.
Western Blot
The HMEC-Cs were stimulated with FGF-2 or HGF as detailed in the Methods section in the online-only Data Supplement. Cardiac samples from the viable zone of the LV after coronary ligation in rats as above were collected at 3 weeks after MI and snap-frozen. Samples were either immunoprecipitated or separated directly by gel electrophoresis followed by membrane transfer for blotting of specific proteins using antihuman total or phosphorylation-specific antibodies as indicated. Results are presented as fold increase over control (time pointϭ0 for cells; MI controls for rats) of the ratio of the band density for the phosphorylated form versus the total amount of the specific protein in the same sample.
Real-Time Polymerase Chain Reaction
The HMEs and HMEC-Cs were stimulated with FGF-2 or HGF as detailed in the Methods section in the online-only Data Supplement. Cardiac samples were collected at 3 weeks after MI. Real-time polymerase chain reaction was performed on a LightCycler (Roche Molecular Biochemicals) with a commercially available mix (Fast-Start DNA Master SYBR Green I kit; Roche). The primer sequences are listed in the Methods section in the online-only Data Supplement. Differences in relative expression levels were calculated according to the ⌬⌬Ct (cycle threshold) method by Pfaffer et al.
Statistics
Data are presented as meanϮSEM. The Student t test (2 tailed) was used to compare 2 groups of independent samples. For multiple comparisons, 1-way ANOVA was used followed by the Tukey post hoc test. Echocardiographic data were analyzed by repeated measures 2-way ANOVA followed by Bonferroni posthoc test. Data sets with nongaussian distribution were analyzed by nonparametric Kruskal-Wallis followed by the Dunn post hoc test. Values of PϽ0.05 were considered significant.
Results

Fibroblast Growth Factor-2 and Hepatocyte Growth Factor Synergistically Stimulate Vascular Cell Migration and Proliferation and Induce Stable Blood Vessel Growth
We evaluated the effects of FGF-2 and/or HGF in vitro using murine HMEs, murine embryonic microvascular ECs, HMEC-Cs, and rat aortic SMCs. Whereas both FGF-2 and HGF used alone induced EC and SMC migration and proliferation ( Figure 1 ), HGF pretreatment significantly potentiated EC motility response to FGF-2 ( Figure 1A and 1B) . Reciprocally, pretreatment with FGF-2 enhanced HGF-induced migration ( Figure 1A and 1B and Figure I in the online-only Data Supplement). Similarly, in SMCs, FGF-2 strikingly increased motility responses to HGF, although HGF did not alter FGF-2-induced migration ( Figure 1C ). Furthermore, pretreatment of HMEC-Cs ( Figure 1D ) or HMEs ( Figure 1E ) with FGF-2 significantly increased HGF-induced cell proliferation. Conversely, pretreatment of HMEC-C ( Figure 1G ) or SMCs ( Figure 1F) with HGF significantly increased cell proliferation responses to FGF-2. These data show that FGF-2 and HGF synergistically stimulate both EC and SMC migration and proliferation, suggesting that this growth factor combination may generate mature and thus stable blood vessels in vivo. To investigate this possibility, we applied the corneal angiogenesis assay. Whereas HGF used alone induced a potent angiogenic response within 1 week as previously reported, 15 most new blood vessels had regressed within 1 month (data not shown). In contrast, the blood vessels induced by FGF-2 used alone or in combination with HGF remained largely intact throughout the first month after initial remodeling ( Figure 1H ). However, whereas after Ϸ1 year only a few vessels remained in FGF-2-implanted corneas, considerably more extensive vascular networks persisted in corneas implanted with HGF and FGF-2.
Sequential Slow Release of Growth Factors by Albumin-Alginate Microcapsules
Next, we aimed to obtain an injectable particulate growth factor delivery system to achieve spatiotemporally controlled release inside the myocardium. Alginate, a naturally occurring polysaccharide, is suitable for the delivery of positively charged proteins such as FGF-2 and HGF because it bears negatively charged carboxylic groups available for electrostatic interactions. 22 Indeed, ionically cross-linked alginate hydrogels have been widely used for angiogenic growth factor delivery 23 but generally display uncontrolled degradation, leading to unpredictable release kinetics. 24 However, covalently cross-linking polysaccharides to proteins in a microcapsule membrane prevents hydrolysis-driven dissolution and delays protease-driven degradation, resulting in more stable particles with reproducible drug release rates. 16, 17 Thus, we developed microcapsules containing a thin, covalently cross-linked human serum albumin and propylene glycol alginate membrane surrounding a liquid center. Laser diffraction measurements and microscopic observations revealed that these albumin-alginate microcapsules had a mean diameter of 100 m and were roughly spherical ( Figure IIA in the online-only Data Supplement). Dehydration caused a partial and reversible collapse, resulting in the appearance of a very pleated surface in desiccated microcapsules as observed by scanning electron microscopy ( Figure IIB in the online-only Data Supplement). The microcapsules were assayed in vitro for the release of angiogenic growth factors under conditions approximating the in vivo tissue environment. Whereas FGF-2 release from the microcapsules began immediately, the release of HGF and another angiogenic growth factor, platelet-derived growth factor (PDGF)-BB, was delayed for Ͼ1 week (Figures IIC and IIIA in the online-only Data Supplement). Furthermore, whereas PDGF-BB release lasted 4 weeks, that of FGF-2 and HGF lasted 6 weeks. We confirmed that the growth factors released from the microcapsules retained their full bioactivity using an in vitro assay ( Figure IIIB in the online-only Data Supplement).
To investigate the stability of the microcapsules, we analyzed their morphology during in vitro incubation. Although FGF-2-loaded microcapsules started to disintegrate within 1 week, those loaded with HGF remained largely intact for 3 to 4 weeks ( Figure IIIC in the online-only Data Supplement). Furthermore, to determine the growth factor localization, we performed confocal analyses of microcap-sules loaded with fluorescently labeled FGF-2 or HGF ( Figure IID and IIE in the online-only Data Supplement). The results show that although both growth factors bound to the microcapsule surface layer, confirming their interactions with the cross-linked protein-polysaccharide membrane, FGF-2 was also found in the liquid center of the microcapsule. These findings may in part explain why the microcapsules display different release profiles for FGF-2 and HGF.
Sustained Delivery of Fibroblast Growth Factor-2 and Hepatocyte Growth Factor Enhances Angiogenic and Arteriogenic Responses
To determine whether our slow-release system would influence the angiogenic effect of FGF-2 or HGF in vivo, we compared treatment with growth factor-loaded microcapsules and naked growth factors using the mouse Matrigel plug model. Growth factor delivery by microcapsules was found to be 3 to 6 times more potent to induce angiogenesis compared with bolus delivery of growth factors ( Figure IIID in the online-only Data Supplement).
The reciprocal stimulatory interactions observed between FGF-2 and HGF in vascular cells indicated that these growth factors may cooperatively regulate vessel growth. To further investigate this possibility, microcapsules containing FGF-2 and/or HGF were injected in Matrigel plugs in mice. In each case, we used the lowest dose of growth factor resulting in a substantial angiogenic effect. Whereas each growth factor used alone induced a moderate angiogenic response, FGF-2 and HGF used in combination synergistically stimulated angiogenesis and arteriogenesis, as evidenced by the increased vascular density (Figure 2A and 2C) , vascular maturity ( Figure 2D) , and vascularized area ( Figure 2E ) compared with single growth factor treatments. The most potent angiogenic growth factor combination described to date is the association of FGF-2 and PDGF-BB. 12 To compare these growth factor combinations, microcapsules containing FGF-2 and/or PDGF-BB were injected in Matrigel plugs in mice. We found that whereas the vessel density induced by the combination of FGF-2 and PDGF-BB ( Figure 2B , 2F, and 2I) was moderately greater than that induced by FGF-2 in combination with HGF, the number of mature vessels did not differ ( Figure 2G and 2J ). However, whereas FGF-2 together with PDGF-BB resulted in only 30% of the total plug area being vascularized, the combination of FGF-2 and HGF notably resulted in a Matrigel plug vessel content of Ϸ80% (Figure 2E and 2H) . These results reveal our microcapsules to be particularly efficient for growth factor delivery in vivo. Furthermore, in agreement with the in vitro data, the combination of FGF-2 and HGF synergistically induced angiogenesis and arteriogenesis at a level comparable to or surpassing that of the most potent angiogenic growth factor combination currently described. 12
Intramyocardial Delivery of Fibroblast Growth Factor-2 and Hepatocyte Growth Factor Stimulates Angiogenesis and Arteriogenesis and Prevents Myocardial Infarction-Induced Cardiac Hypertrophy and Fibrosis
To evaluate the effect of FGF-2 in combination with HGF in a setting of cardiovascular disease, we performed a randomized, blinded experiment in rats surviving coronary artery ligation (nϭ102) or sham surgery (nϭ11). The experimental MI model leads to the development of CHF within 3 months. 18 We found that the albumin-alginate microcapsules displayed slow release of HGF or FGF-2 in vivo after intramyocardial injection in rats ( Figure IV in the online-only Data Supplement). Thus, we used these microcapsules for cardiac delivery of angiogenic factors by local injection into the viable free wall of the myocardium bordering the LV infarct zone immediately after MI ( Figure VA in the onlineonly Data Supplement). At 1 or 3 months after MI, the angiogenic and arteriogenic cardiac effects were evaluated by immunohistochemistry. At 1 month after MI, untreated controls displayed myocardial vessel rarefaction, including reduced levels of mature blood vessels, compared with healthy shams (1552Ϯ71 versus 2489Ϯ93 vessels per 1 mm 2 ; Figure  VB and VC in the online-only Data Supplement). The reduction was limited mainly to SMA ϩ microvessels with lumen diameters inferior to 15 m ( Figure VIA and VIB in the online-only Data Supplement). As a result of an inherent compensatory angiogenic response, evidenced by increased EC proliferation ( Figure VD in the online-only Data Supplement), the total vessel (1848Ϯ57 vessels per 1 mm 2 ) and mature vessel densities were slightly improved in untreated control hearts at 3 months ( Figure 3A through 3D) . Monotherapy with FGF-2 resulted in a further increase in angio-genesis and arteriogenesis locally in the treated LV area, leading to slightly augmented vessel density (1809Ϯ83 vessels per 1 mm 2 ) and significantly increased mature vessel density at 1 month compared with controls. However, the effects were lost at 3 months (1839Ϯ84 vessels per 1 mm 2 ; Figure 3A through 3E). Monotherapy with HGF, on the other hand, showing limited arteriogenic effects at 1 month, tended to increase EC proliferation and vascular density at 3 months (2107Ϯ80 vessels per 1 mm 2 ; Figure 3A , 3C, and 3E). In contrast, the combination therapy induced a potent angiogenic (1919Ϯ66 vessels per 1 mm 2 ) and arteriogenic response, again strictly limited to the treated LV zone, with more than a doubling of the number of proliferating ECs ( Figure VD in the online-only Data Supplement) and 3 times more mature blood vessels compared with untreated controls at 1 month after MI ( Figure VC in the online-only Data Supplement). The increase in SMA ϩ vessels was due mainly to an increase in microvessels ( Figure VIA and VIB in the online-only Data Supplement). Strikingly, by 3 months, the myocardial vessel density in the combination group had attained normal sham levels (2505Ϯ106 vessels per 1 mm 2 ; Figure 3A and 3C). Moreover, the mature vessel density in the group treated by the combination even surpassed that of shams ( Figure 3B and 3D ). Furthermore, whereas the numbers of SMA ϩ microvessels had decreased, there was a significant increase in the number of small arterioles with lumen diameters between 15 and 50 m ( Figure VIC and VID in the online-only Data Supplement), suggestive of vascular remodeling.
Next, the extent of MI-induced cardiac hypertrophy and fibrosis was evaluated by histological analyses of cardiomyocyte sizes and collagen density, respectively. At 1 month, cardiomyocyte sizes were not significantly increased in MI controls compared with sham, although the mRNA level of the maladaptive cardiac hypertrophic marker ␤-myosin heavy chain was found to be increased, together with significantly higher expression levels of atrial natriuretic peptide and a tendency for increased brain natriuretic peptide ( Figure VII in the online-only Data Supplement). In contrast, FGF-2 used alone or in combination with HGF tended to stimulate cardiac hypertrophy (data not shown), although it did not reach significance. This is in line with previous studies suggesting a direct stimulatory role of angiogenesis on cardiac hypertrophy. 25 However, the cardiomyocyte hypertrophy was not associated with increased ␤-myosin heavy chain, suggesting, together with the increased vessel density observed, that the cardiomyocyte growth may have been adaptive. At 3 months, MI controls and FGF-2-treated rats showed equally enlarged cardiomyocytes and increased levels of collagen deposition compared with sham ( Figure 3F and 3G) . In contrast, both HGF alone and the combination treatment significantly reduced cardiac fibrosis and hypertrophy at 3 months. In agreement, the ratio of LV weight to body weight that was significantly increased in MI controls compared with sham was reduced by the combination treatment (data not shown). Importantly, the coordinated decrease in cardiomyocyte sizes and increase in blood vessel density generated by the combination treatment resulted in a normalization of the ratio of cardiomyocytes to vessel ( Figure 3H ).
We also verified the cardiac distribution of the slowdelivery vehicles using fluorescently labeled microcapsules. Hearts were evaluated histologically at 6 hours and 1 or 2 weeks after intramyocardial injection. We found that the microcapsules were confined in a small area surrounding the 3 injection points, extending maximally 1 to 2 mm into the subepicardial myocardium ( Figure VIII) . The microcapsules spread over an area representing Ϸ8% of a cross section of the LV at the papillary muscle level after 6 hours, progressively decreasing to Ϸ6% after 1 week and 4.5% after 2 weeks. These findings confirm a localized microcapsule distribution centered around the points of injections, in agreement with the observed restricted LV effects of the therapies, and a comparable timeline of microcapsule degradation in the heart as seen in vitro.
Intramyocardial Delivery of Fibroblast Growth Factor-2 and Hepatocyte Growth Factor Improves Regional Cardiac Perfusion and Cardiac Function After Myocardial Infarction
To assess whether the blood vessels induced by the angiogenic therapies resulted in a functional improvement in cardiac perfusion, magnetic resonance imaging was used. Our results, obtained 3 months after MI, demonstrate that whereas untreated controls displayed significantly reduced cardiac perfusion compared with healthy sham-operated animals, only the combination treatment increased regional cardiac perfusion in the treated area of the LV ( Figure 4A ).
Next, to investigate whether the multiple beneficial myocardial alterations induced by the angiogenic therapies correlated with improved cardiac function, even though myocardial infarct sizes were similar in all groups ( Figure IX in the online-only Data Supplement), echocardiographic analyses were carried out at 1 and 3 months after MI. As previously reported, 18 Tables I and II in the online-only Data Supplement). Both regional and global cardiac contractility were reduced, as evidenced at 1 month by a decreased fractional shortening (FS; 16Ϯ1% for control versus 54Ϯ3% for sham; Figure 4E ) and velocity of circumferential fiber shortening ( Figure 4F ). Monotherapy with HGF only slightly improved LV parameters by 3 months, as evidenced by a decreased LVESD and end-systolic volume ( Table II in Tables I and II in the online-only Data Supplement) and, by 3 months after MI, increased both FS ( Figure 4E ) and velocity of circumferential fiber shortening ( Figure 4F) .
In contrast to these moderate effects of monotherapies, the combination of FGF-2 and HGF reduced LV dilation ( Figure  4B and 4D; LVESD and LVEDD in Table I in the online-only Data Supplement) and LV dysfunction already at 1 month after MI, as shown by an increased FS (22Ϯ2%; Figure 4E ) compared with untreated controls. This was associated with a tendency for increased velocity of circumferential fiber shortening ( Figure 4F ), LV anterior end-systolic wall thickness ( Table I in the online-only Data Supplement), and wall thickening ( Figure 4C) . At 3 months, the combination treatment group displayed a significant further increase in LV wall thickness (anterior end-systolic and end-diastolic wall thickness, Table II in the online-only Data Supplement), and wall thickening was no longer significantly different from that of sham rats ( Figure 4C) . Moreover, the LV dilation was further reduced ( Figure 4D ; LVEDD and LVESD, Table II in the online-only Data Supplement) and associated with a marked recovery of LV function, evidenced by an increased FS ( Figure 4E ) and velocity of circumferential fiber shortening ( Figure 4F ) compared with both untreated controls and HGF-treated animals, indicating that the development of CHF was partially prevented.
Molecular Mechanisms of the Angiogenic Synergy
To investigate potential molecular mechanisms behind the observed synergy between FGF-2 and HGF, the effects on different signaling pathways were analyzed in ECs. The levels of phospho-Akt (p-Akt) and phospho-42/44 mitogen-activated protein kinases (p-MAPKs) were assayed in HMEC-Cs after stimulation with FGF-2 and/or HGF. We found that FGF-2 induced maximal Akt activation within 10 to 15 minutes (1.7Ϯ0.5-fold induction over control) but p-Akt levels returned to baseline after 30 minutes ( Figure 5A and 5C). In turn, HGF induced maximal Akt activation within 30 minutes (1.6Ϯ0.5-fold). The increased levels of p-Akt persisted up to 1 hour, consistent with the potent antiapoptotic effects of HGF. 26 Notably, the combination of FGF-2 with HGF induced a prolonged Akt activation lasting Ͼ2 hours, with a significantly increased maximal activation level (2.2Ϯ0.2-fold). Next, we found that FGF-2 induced maximal p 42/44 -MAPK activation within 15 minutes (1.8Ϯ0.6 fold; Figure 5B and 5D). In addition, HGF activated p 42/44 -MAPK, with a maximal effect after 30 minutes (2.4Ϯ0.8-fold) persisting for Ͼ1 hour. The combination of FGF-2 and HGF resulted in a strikingly potent MAPK activation within 10 to 15 minutes (5.8Ϯ1.0-fold). However, the signal duration was only slightly prolonged compared with single growth factor stimulation. To verify that synergistic activation of cell signaling pathways also may occur in vivo, we assayed the levels of p-Akt in cardiac samples obtained at 3 weeks after MI. We found that the combination treatment led to significantly increased Akt activation compared with MI controls ( Figure XA and XB in the online-only Data Supplement).
Another mechanism by which dual growth factor treatment may produce synergistic effects involves the induction of growth factor receptor levels. For instance, the potent angiogenic synergy between FGF-2 and PDGF-BB is due in part to an upregulation in vascular cells of FGFR-1 by PDGF-BB and of PDGF receptors by FGF-2. 12, 27 To investigate whether similar mechanisms may operate in the combination of FGF-2 with HGF, real-time polymerase chain reaction analyses were performed in vascular cells. Indeed, we found that HGF stimulation significantly induced the expression of both FGFR-1 ( Figure 5F ) and the HGF receptor c-Met ( Figure 5E ) in murine HMEs. In a reciprocal manner, FGF-2 stimulation potently increased c-Met mRNA levels ( Figure 5E ) while displaying a weaker effect on FGFR-1 levels ( Figure 5F ). Similar results were obtained in human HMEC-Cs ( Figure  5G and 5H) . Moreover, we found that FGF-2 induced the expression of c-Met in rat SMCs (data not shown). Next, to . The combination (HϩF) of fibroblast growth factor-2 (FGF-2) and hepatocyte growth factor (HGF) improves cardiac perfusion and function after myocardial infarction. Regional cardiac perfusion (mL ⅐ min Ϫ1 ⅐ g Ϫ1 ) evaluated by magnetic resonance imaging after 3 months (A). Typical echocardiographic tracings at 3 months after MI (B). Regional and global cardiac function evaluated by echocardiography after 1 and 3 months: anterior wall thickening (%; C), left ventricular (LV) end-diastolic diameter (mm; D), and fractional shortening (%; E) calculated from short-axis measurements (see Tables I and II in confirm these findings in vivo, FGFR-1 and c-Met protein levels were assayed by semiquantitative immunofluorescence analyses of mouse Matrigel plugs. We found that although vascular c-Met levels were comparable after 3 weeks of stimulation with either FGF-2 or HGF, the FGFR-1 levels were increased in blood vessels induced by HGF compared with FGF-2 ( Figure 5I and 5J).
To extend these findings to the heart, we assayed by Western blot the levels of phosphorylated FGFR-1 or c-Met in the treated LV peri-infarct zone at 3 weeks after MI. We found that FGF-2 treatment used alone or together with HGF resulted in increased levels of activated FGFR-1 compared with MI controls ( Figure  XB and XC in the online-only Data Supplement). Similarly, HGF treatment used alone significantly increased phospho-FGFR-1 levels in the heart. Reciprocally, FGF-2 used alone increased the levels of phospho-c-Met to levels similar to those with HGF treatment used alone or together with FGF-2 ( Figure  XE and XF in the online-only Data Supplement). Taken together, this finding suggests that whereas FGF-2 may have induced HGF and/or c-Met expression, HGF may have induced FGF-2 and/or FGFR-1 expression in the heart, in line with our in vitro findings in vascular cells.
Discussion
Current strategies of therapeutic angiogenesis or arteriogenesis in cardiovascular diseases, including CHF, have proved insufficient. Our study shows that therapeutic angiogenesis, based on targeted intramyocardial albumin-alginate microcapsule delivery of a synergistic combination of growth factors, results in potent stimulation of mature blood vessel growth, prevention of cardiac remodeling, and enhanced myocardial perfusion and cardiac function in a rat model of post-MI CHF.
HGF plays an important role in tissue regeneration. It displays considerable prosurvival effects in many cell types, including cardiomyocytes. In addition, HGF potently stimulates angiogenesis. 28 During tissue ischemia, HGF and its receptor, cMet, are upregulated in vascular cells and cardiomyocytes. 29 Most recently, encouraging results have been reported for a double-blind controlled HGF gene therapy trial for chronic limb ischemia, 30 suggesting the utility of this particular growth factor for regenerative medicine. Interestingly, in the present study, we found that HGF monotherapy at a dose at least 1 to 2 orders of magnitude lower than most experimental studies, while efficiently preventing cardiac fibrosis and hypertrophy, had limited angiogenic effects. Thus, although the structural antiremodeling effects were indeed considerable, the fact that HGF monotherapy merely showed weak amelioration of cardiac function suggests that stimulation of angiogenesis and arteriogenesis plays a key role in prevention of cardiac dysfunction. However, whereas FGF-2 monotherapy failed to induce a stable increase in blood vessel density and further showed no effects on cardiac fibrosis or hypertrophy, it did successfully improve regional cardiac function, as evidenced by decreased LVESD and increased FS. This suggests that mechanisms other than stimula- Figure 5 . Molecular cross-talk between fibroblast growth factor-2 (FGF-2) and hepatocyte growth factor (HGF). Akt (A, C), and mitogen-activated protein kinase (MAPK; B and D) activation levels assayed in human microvascular cardiac endothelial cells (HMEC-Cs) stimulated with FGF-2 and/or HGF for different times (0, 1.5, 10, 15, 30, 60, or 120 minutes). Results are presented as the ratio of phospho-Akt or phospho-MAPK to Akt or MAPK, respectively, in the same sample. Angiogenic growth factor receptor mRNA levels in HME (E and F) and HMEC-Cs (G and H). Angiogenic growth factor receptor protein levels in Matrigel plugs stimulated by HGF or FGF-2 in vivo (I). Examples of FGF receptor-1 (FGFR-1) signal (red) in blood vessels (green, indicated by white arrows) induced by HGF (left) or FGF-2 (right). Scale barϭ100 m (J). C and D, #PϽ0.05 vs FGF-2; *PϽ0.05 vs FGF-2 or HGF. E through H, *PϽ0.05, **PϽ0.01, ***PϽ0.001 vs control. tion of angiogenesis were at play. Indeed, FGF-2 may have direct cardioprotective effects involving decreased cell-to-cell metabolic coupling in cardiomyocytes through inhibition of connexin-43 gap junctions. 31 Thus, it seems probable that the improvement in both regional and global cardiac function observed with the combination of FGF-2 and HGF is multifactorial in origin and not due only to potent induction of arteriogenesis leading to a normalized ratio of cardiomyocytes to vessel and enhanced regional cardiac perfusion.
The cardiac fibrosis occurring during postinfarction remodeling causes increased ventricular wall stiffness and reduced cardiac relaxation rates, contributing to the cardiac dysfunction. HGF has been shown to reduce cardiac fibrosis, in part via suppression of transforming growth factor-␤ signaling. 32 Similarly, in our study, we found that HGF used alone or in combination with FGF-2 resulted in an impressive reduction of cardiac collagen content. This antifibrotic effect of HGF may have played an important role in the observed cardiac functional improvement induced by the combination treatment.
With regard to the potential molecular mechanisms behind the observed angiogenic synergy, we found that the combination of FGF-2 and HGF significantly potentiated the activation of Akt and MAPKs compared with single growth factors. This may contribute to the synergistic stimulation of cellular migration and proliferation observed in vitro and to the potent angiogenic effects in vivo. Moreover, we found evidence, both in vitro and in vivo, that HGF induces FGFR-1 levels in ECs, which should lead to enhanced FGF-2-induced signaling. Similar results were found in human ECs in which FGF-2 also reciprocally increased c-Met levels.
Previous studies have indicated some further potential means of angiogenic interactions, including HGF induction in SMCs by FGF-2. Moreover, HGF induces vascular endothelial growth factor production in SMCs and has been suggested to act in synergy with vascular endothelial growth factor to induce EC migration. 33 However, another study reported that HGF and vascular endothelial growth factor did not synergistically stimulate angiogenesis in vivo and further that vascular endothelial growth factor was not required for the angiogenic effects of HGF. 34 Interestingly, the proarteriogenic signal of angiopoietin-1 has been shown to depend on induction of HGF in ECs, 35 suggesting that HGF is indeed a key mediator of vascular maturation similar to PDGF-BB.
Whereas angiogenesis generally requires prolonged stimulation of vascular cells, the in vivo half-life of most angiogenic growth factors is very limited, illustrating the need to incorporate sustained delivery systems for protein therapy approaches. 36 In this study, we devised albumin-alginate microcapsules to gain spatiotemporal control over growth factor release. These microcapsules released active growth factors over a significant period of time, showing different release kinetics for FGF-2 versus HGF. This sequential release pattern, generating an initial strong angiogenic signal through FGF-2 followed by a potent arteriogenic signal via HGF, might be ideal to induce mature blood vessel formation. Furthermore, our sustained release system not only increased the efficacy of treatment, permitting the use of remarkably low doses of growth factors, but also resulted in the confinement of the angiogenic effect to a well-defined area of the LV. Both of these aspects should be instrumental in considerably reducing growth factor leakage to the circulation and thus the risk for serious side effects of treatment, including stimulation of angiogenesis at distant sites potentially harboring micrometastases.
Conclusions
Our data provide proof of principle that localized sustained delivery of low doses of a specific combination of angiogenic growth factors is sufficient to generate stable and functional blood vessels in the heart. Moreover, dual delivery of FGF-2 and HGF reduced MI-induced cardiac fibrosis and remodeling and partially prevented cardiac dysfunction. These findings may provide conceptual guidelines for future clinical trials of therapeutic angiogenesis for the treatment of cardiovascular diseases.
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